Navco Pharmaceuticals Inc.
NAV.V
TSX
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -97.53% | -82.82% | -77.13% | 1,154.21% | 211.91% |
| Depreciation & Amortization | -93.83% | -93.90% | 222.78% | 146.91% | 0.00% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -97.37% | -82.98% | -71.21% | 877.63% | 186.41% |
| Operating Income | 97.37% | 82.98% | 71.21% | -877.63% | -186.41% |
| Income Before Tax | 96.25% | -164.56% | 94.79% | -819.06% | -184.76% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 96.25% | -164.56% | 94.79% | -819.06% | -184.76% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 96.25% | -164.56% | 94.79% | -819.06% | -184.76% |
| EBIT | 97.37% | 82.98% | 71.21% | -877.63% | -186.41% |
| EBITDA | 103.23% | 84.74% | 76.46% | -1,166.36% | -211.91% |
| EPS Basic | 98.00% | -145.75% | 96.27% | -150.00% | -51.52% |
| Normalized Basic EPS | 96.77% | 87.78% | 76.92% | -142.86% | -47.62% |
| EPS Diluted | 98.00% | -145.75% | 96.27% | -150.00% | -51.52% |
| Normalized Diluted EPS | 96.77% | 87.78% | 76.92% | -142.86% | -47.62% |
| Average Basic Shares Outstanding | 41.43% | 41.53% | 37.34% | 270.53% | 89.08% |
| Average Diluted Shares Outstanding | 41.43% | 41.53% | 37.34% | 270.53% | 89.08% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |